Current:Home > StocksIneffective ingredient could make Dayquil, Sudafed and others disappear from store shelves-LoTradeCoin
Ineffective ingredient could make Dayquil, Sudafed and others disappear from store shelves
View Date:2024-12-24 09:40:49
Pharmacies could pull common over-the-counter cold medications, including Dayquil, Sudafed and Theraflu, from store shelves after Food and Drug Administration experts determined one of the drugs' main ingredient doesn't work.
That could leave consumers scrambling to find alternative treatments for relief from nasal congestion and drugmakers hurrying to devise new drug formulations.
Drugs like Sudafed, made by pharmaceutical company Johnson & Johnson, are part of a roughly $2.2 billion market for oral decongestants. Products with formulations that contain phenylephrine, the drug FDA experts deemed ineffective, make up about four-fifths of that market.
"Unintended consequences"?
The Consumer Healthcare Products Association (CPHA) maintains that phenylephrine is effective and that the FDA's guidance could have significant "negative unintended consequences." Pulling drugs like Sudafed from store shelves would make it harder for consumers to treat mild illnesses, according to the industry trade group.
Removing popular over-the-counter medications from the market would force some people "to find time to seek help from a pharmacist, doctor or clinic for an oral decongestant for a minor ailment they could otherwise self-treat," the group said in a statement before the determination was made.
"Additionally, some consumers indicate they might delay or forgo treatment, which could lead to worsened clinical outcomes such as progression to acute sinusitis and increased demand for doctor and clinic visits over time," CPHA said.
Which drugs contain phenylephrine?
Phenylephrine is found in these and other OTC remedies for stuffy noses:
- Mucinex Sinus-Max
- Robitussin Peak Cold Nighttime Nasal Relief
- Sudafed PE Sinus Congestion
- Theraflu
- Vicks DayQuil and NyQuil Severe Cold & Flu
Phenylephrine is also found in other types of products, such as hemorrhoid creams, but was only deemed ineffective as an ingredient in oral form.
How big is the market for these drugs?
All told, decongestants with phenylephrine account for roughly $1.8 billion in annual sales, according to an FDA report.
Drugmakers also market a separate class of nasal decongestants containing pseudoephedrine (PSE). In 2006, OTC medications containing PSE were moved behind the pharmacy counter because of concerns they could be used to make illicit methamphetamines, which is when formulations with phenylephrine became more popular.
In 2022, stores sold roughly 242 million bottles or packages of OTC cold and allergy oral medications containing phenylephrine, according to the FDA. By comparison, stores that same year sold an estimated 51 million units of PSE, representing $542 million in sales in 2022.
"Sales of products containing PE, which amounted to only a small percentage of the market prior to 2006, have risen and displaced products containing PSE as an OTC decongestant, although sales of PSE, while smaller, remain," the FDA concluded.
The federal agency also acknowledged the potential "negative" impact that pulling oral PE products from shelves could have on consumers.
- In:
- FDA
veryGood! (48859)
Related
- Tech consultant testifies that ‘bad joke’ led to deadly clash with Cash App founder Bob Lee
- In Alaska’s North, Covid-19 Has Not Stopped the Trump Administration’s Quest to Drill for Oil
- Florida dog attack leaves 6-year-old boy dead
- The Best Protection For Forests? The People Who Live In Them.
- The results are in: Peanut the Squirrel did not have rabies, county official says
- Need an apartment? Prepare to fight it out with many other renters
- Where Tom Schwartz Stands With Tom Sandoval After Incredibly Messed Up Affair With Raquel Leviss
- 16 Amazon Beach Day Essentials For the Best Hassle-Free Summer Vacay
- As CFP rankings punish SEC teams, do we smell bias against this proud and mighty league?
- Polluting Industries Cash-In on COVID, Harming Climate in the Process
Ranking
- 'Serial swatter': 18-year-old pleads guilty to making nearly 400 bomb threats, mass shooting calls
- Twitter threatens legal action over Meta's copycat Threads, report says
- U.S. expected to announce cluster munitions in new package for Ukraine
- An Indiana Church Fights for Solar Net-Metering to Save Low-Income Seniors Money
- After entire police force resigns in small Oklahoma town, chief blames leaders, budget cuts
- Fortnite maker Epic Games will pay $520 million to settle privacy and deception cases
- Inside Chris Evans' Private Romance With Alba Baptista
- Everwood Star Treat Williams Dead at 71 in Motorcycle Accident
Recommendation
-
'Unfortunate error': 'Wicked' dolls with porn site on packaging pulled from Target, Amazon
-
Warming Trends: A Facebook Plan to Debunk Climate Myths, ‘Meltdown’ and a Sad Yeti
-
Jon Hamm's James Kennedy Impression Is the Best Thing You'll See All Week
-
Many Nations Receive Failing Scores on Climate Change and Health
-
Jake Paul's only loss led him to retool the team preparing him to face Mike Tyson
-
Russian fighter pilots harass U.S. military drones in Syria for second straight day, Pentagon says
-
Twitter threatens legal action over Meta's copycat Threads, report says
-
U.S. saw 26 mass shootings in first 5 days of July alone, Gun Violence Archive says